TrialThe Journal of infectious diseases2011

Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy.

Peter W Hunt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.